Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the

Hopkins, Brian T.; Bame, Eris; Bajrami, Bekim; Black, Cheryl; Bohnert, Tonika; Boiselle, Carrie; Burdette, Doug; Burns, Jeremy C.; Delva, Luisette; Donaldson, Douglas; Grater, Richard; Gu, Chungang; Hoemberger, Marc; Johnson, Josh; Kapadnis, Sudarshan; King, Kris; Lulla, Mukesh; Ma, Bin; Marx, Isaac; Magee, Tom; Meissner, Robert; Metrick, Claire M.; Mingueneau, Michael; Murugan, Paramasivam; Otipoby, Kevin L.; Polack, Evelyne; Poreci, Urjana; Prince, Robin; Roach, Allie M.; Rowbottom, Chris; Santoro, Joseph C.; Schroeder, Patricia; Tang, Hao; Tien, Eric; Zhang, Fengmei; Lyssikatos, Joseph

doi:10.1021/acs.jmedchem.1c00926

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the

Journal Article · 01 January 2022 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.1c00926· OSTI ID:1844739

Hopkins, Brian T.; Bame, Eris; Bajrami, Bekim; Black, Cheryl; Bohnert, Tonika; Boiselle, Carrie; Burdette, Doug; Burns, Jeremy C.; Delva, Luisette; Donaldson, Douglas; Grater, Richard; Gu, Chungang; Hoemberger, Marc; Johnson, Josh; Kapadnis, Sudarshan; King, Kris; Lulla, Mukesh; Ma, Bin; Marx, Isaac; Magee, Tom more »

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1844739

Journal Information:: J. Med. Chem., Journal Name: J. Med. Chem. Journal Issue: (2) Vol. 65

Country of Publication:: United States

Language:: ENGLISH

References (42)

Identifying the Roles of Amino Acids, Alcohols and 1,2-Diamines as Mediators in Coupling of Haloarenes to Arenes Zhou, Shengze; Doni, Eswararao; Anderson, Greg M. Journal of the American Chemical Society, Vol. 136, Issue 51 https://doi.org/10.1021/ja5101036	journal	December 2014
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis Montalban, Xavier; Arnold, Douglas L.; Weber, Martin S. New England Journal of Medicine, Vol. 380, Issue 25 https://doi.org/10.1056/NEJMoa1901981	journal	June 2019
Oxetane Substrates of Human Microsomal Epoxide Hydrolase Toselli, Francesca; Fredenwall, Marlene; Svensson, Peder Drug Metabolism and Disposition, Vol. 45, Issue 8 https://doi.org/10.1124/dmd.117.076489	journal	June 2017
Zanubrutinib: First Approval Syed, Yahiya Y. Drugs, Vol. 80, Issue 1 https://doi.org/10.1007/s40265-019-01252-4	journal	January 2020
Applications of Fluorine in Medicinal Chemistry Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D. Journal of Medicinal Chemistry, Vol. 58, Issue 21 https://doi.org/10.1021/acs.jmedchem.5b00258	journal	July 2015
Managing toxicities of Bruton tyrosine kinase inhibitors Lipsky, Andrew; Lamanna, Nicole Hematology, Vol. 2020, Issue 1 https://doi.org/10.1182/hematology.2020000118	journal	December 2020
Synthesis and evaluation of CS-2100, a potent, orally active and S1P3- sparing S1P1 agonist Nakamura, Tsuyoshi; Asano, Masayoshi; Sekiguchi, Yukiko European Journal of Medicinal Chemistry, Vol. 51 https://doi.org/10.1016/j.ejmech.2012.02.022	journal	May 2012
Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz Nature Chemical Biology, Vol. 7, Issue 1 https://doi.org/10.1038/nchembio.481	journal	November 2010
In vitro models for liver toxicity testing Soldatow, Valerie Y.; LeCluyse, Edward L.; Griffith, Linda G. Toxicol. Res., Vol. 2, Issue 1 https://doi.org/10.1039/C2TX20051A	journal	January 2013
B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies Puri, Kamal D.; Di Paolo, Julie A.; Gold, Michael R. International Reviews of Immunology, Vol. 32, Issue 4 https://doi.org/10.3109/08830185.2013.818140	journal	July 2013
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases: Crystal Structures of Human BTK Kinase Domain Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M. Protein Science, Vol. 19, Issue 3 https://doi.org/10.1002/pro.321	journal	January 2010
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia: Journal of Clinical Pharmacology Li, Yan; Ramírez-Valle, Francisco; Xue, Yongjun The Journal of Clinical Pharmacology, Vol. 57, Issue 10 https://doi.org/10.1002/jcph.923	journal	May 2017
Mechanistic Investigation of the Staudinger Ligation Lin, Fiona L.; Hoyt, Helen M.; van Halbeek, Herman Journal of the American Chemical Society, Vol. 127, Issue 8 https://doi.org/10.1021/ja044461m	journal	March 2005
HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis Park, Jin Kyun; Byun, Joo-Yun; Park, Ji Ah Arthritis Research & Therapy, Vol. 18, Issue 1 https://doi.org/10.1186/s13075-016-0988-z	journal	April 2016
Antiarthritis Effect of a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships between Inhibition of BTK Phosphorylation and Efficacy Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim Journal of Pharmacology and Experimental Therapeutics, Vol. 338, Issue 1 https://doi.org/10.1124/jpet.111.181545	journal	April 2011
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells Bame, Eris; Tang, Hao; Burns, Jeremy C. Clinical & Translational Immunology, Vol. 10, Issue 6 https://doi.org/10.1002/cti2.1295	journal	January 2021
Tec Family Kinases in t Lymphocyte Development and Function Berg, Leslie J.; Finkelstein, Lisa D.; Lucas, Julie A. Annual Review of Immunology, Vol. 23, Issue 1 https://doi.org/10.1146/annurev.immunol.22.012703.104743	journal	April 2005
Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L. Journal of Medicinal Chemistry, Vol. 63, Issue 21 https://doi.org/10.1021/acs.jmedchem.0c00702	journal	July 2020
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development Crawford, James J.; Johnson, Adam R.; Misner, Dinah L. Journal of Medicinal Chemistry, Vol. 61, Issue 6 https://doi.org/10.1021/acs.jmedchem.7b01712	journal	February 2018
The Exploration of Chirality for Improved Druggability within the Human Kinome Saha, Debasmita; Kharbanda, Anupreet; Yan, Wei Journal of Medicinal Chemistry, Vol. 63, Issue 2 https://doi.org/10.1021/acs.jmedchem.9b00640	journal	September 2019
Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia Brown, J. R.; Harb, W. A.; Hill, B. T. Haematologica, Vol. 101, Issue 7 https://doi.org/10.3324/haematol.2015.140806	journal	May 2016
The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity Croxford, Andrew L.; Lanzinger, Margit; Hartmann, Felix J. Immunity, Vol. 43, Issue 3 https://doi.org/10.1016/j.immuni.2015.08.010	journal	September 2015
The use of liquid chromatography/thermospray mass spectrometry with on-line ultraviolet diode array and radiochemical detection: Characterization of the putative metabolites of U-78875 in female rat faeces Speed, W.; Parton, A. H.; Martin, I. J. Biological Mass Spectrometry, Vol. 23, Issue 1 https://doi.org/10.1002/bms.1200230102	journal	January 1994
CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system Mildner, Alexander; Mack, Matthias; Schmidt, Hauke Brain, Vol. 132, Issue 9 https://doi.org/10.1093/brain/awp144	journal	June 2009
Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis Torke, Sebastian; Weber, Martin S. Expert Opinion on Investigational Drugs, Vol. 29, Issue 10 https://doi.org/10.1080/13543784.2020.1807934	journal	August 2020
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial Cohen, Stanley; Tuckwell, Katie; Katsumoto, Tamiko R. Arthritis & Rheumatology, Vol. 72, Issue 9 https://doi.org/10.1002/art.41275	journal	August 2020
Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina Molecular Pharmacology, Vol. 91, Issue 3 https://doi.org/10.1124/mol.116.107037	journal	January 2017
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor Herman, Ann E.; Chinn, Leslie W.; Kotwal, Shweta G. Clinical Pharmacology & Therapeutics, Vol. 103, Issue 6 https://doi.org/10.1002/cpt.1056	journal	March 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis Hauser, Stephen L.; Bar-Or, Amit; Comi, Giancarlo New England Journal of Medicine, Vol. 376, Issue 3 https://doi.org/10.1056/NEJMoa1601277	journal	January 2017
Über neue organische Phosphorverbindungen III. Phosphinmethylenderivate und Phosphinimine Staudinger, H.; Meyer, Jules Helvetica Chimica Acta, Vol. 2, Issue 1, p. 635-646 https://doi.org/10.1002/hlca.19190020164	journal	January 1919
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study Schafer, Peter H.; Kivitz, Alan J.; Ma, Jianglin Rheumatology and Therapy, Vol. 7, Issue 1 https://doi.org/10.1007/s40744-019-00182-7	journal	November 2019
Tricyclic Pyrazoles. 3. Synthesis, Biological Evaluation, and Molecular Modeling of Analogues of the Cannabinoid Antagonist 8-Chloro-1-(2‘,4‘-dichlorophenyl)- N -piperidin-1-yl-1,4,5,6- tetrahydrobenzo[6,7]cyclohepta[1,2- c ]pyrazole-3-carboxamide Murineddu, Gabriele; Ruiu, Stefania; Loriga, Giovanni Journal of Medicinal Chemistry, Vol. 48, Issue 23 https://doi.org/10.1021/jm050317f	journal	October 2005
The influence of drug-like concepts on decision-making in medicinal chemistry Leeson, Paul D.; Springthorpe, Brian Nature Reviews Drug Discovery, Vol. 6, Issue 11 https://doi.org/10.1038/nrd2445	journal	November 2007
phenix.model_vs_data : a high-level tool for the calculation of crystallographic model and data statistics Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Chen, Vincent B. Journal of Applied Crystallography, Vol. 43, Issue 4 https://doi.org/10.1107/S0021889810015608	journal	May 2010
The Role of Tec Family Kinases in Mononuclear Phagocytes Koprulu, Afitap Derya; Ellmeier, Wilfried Critical Reviews™ in Immunology, Vol. 29, Issue 4 https://doi.org/10.1615/CritRevImmunol.v29.i4.30	journal	January 2009
Acalabrutinib and its use in treatment of chronic lymphocytic leukemia Khan, Yasir; O'Brien, Susan Future Oncology, Vol. 15, Issue 6 https://doi.org/10.2217/fon-2018-0637	journal	February 2019
BTK: a two-faced effector in cancer and tumour suppression Rada, Miran; Barlev, Nickolai; Macip, Salvador Cell Death & Disease, Vol. 9, Issue 11 https://doi.org/10.1038/s41419-018-1122-8	journal	October 2018
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer Dienstmann, Rodrigo; De Dosso, Sara; Felip, Enriqueta Molecular Oncology, Vol. 6, Issue 1 https://doi.org/10.1016/j.molonc.2011.11.009	journal	December 2011
Conformational restriction: an effective tactic in 'follow-on'-based drug discovery Fang, Zengjun; Song, Yu’ning; Zhan, Peng Future Medicinal Chemistry, Vol. 6, Issue 8 https://doi.org/10.4155/fmc.14.50	journal	May 2014
Chiral Brønsted Acid Catalyzed Enantioselective Mannich-Type Reaction Yamanaka, Masahiro; Itoh, Junji; Fuchibe, Kohei Journal of the American Chemical Society, Vol. 129, Issue 21 https://doi.org/10.1021/ja0684803	journal	May 2007
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis Chan, Phyllis; Yu, Jiajie; Chinn, Leslie Pharmaceutical Research, Vol. 37, Issue 2 https://doi.org/10.1007/s11095-019-2752-y	journal	January 2020
In silico toxicology: computational methods for the prediction of chemical toxicity: Computational methods for the prediction of chemical toxicity Raies, Arwa B.; Bajic, Vladimir B. Wiley Interdisciplinary Reviews: Computational Molecular Science, Vol. 6, Issue 2 https://doi.org/10.1002/wcms.1240	journal	January 2016

Similar Records

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

Journal Article · 2016 · Leukemia · OSTI ID:1234758

Discovery of 8-Amino-imidazo[1,5- a ]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis

Journal Article · 2015 · ACS Medicinal Chemistry Letters · OSTI ID:1404965

Discovery of 3-morpholino-imidazole[1,5- a ]pyrazine BTK inhibitors for rheumatoid arthritis

Journal Article · 2017 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1404954

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the

Citation Formats

References (42)

Similar Records

Related Subjects